T1	Participants 269 325	patients with EGFR mutation-positive lung adenocarcinoma
T2	Participants 411 564	Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364)
T3	Participants 921 982	population after 209 (LUX-Lung 3) and 237 (LUX-Lung 6) deaths
T4	Participants 1163 1175	345 patients
T5	Participants 2258 2276	patients with EGFR
T6	Participants 2753 2779	229 patients in LUX-Lung 3
T7	Participants 2796 2824	239 patients in LUX-Lung 6),
T8	Participants 3523 3561	patients with Leu858Arg EGFR mutations
